Evidence map›Paper›PMID 39054631›Full record

ArticleAnnals of clinical and translational neurology2024

Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody-associated disease.

Ruth Schneider, Ann-Kathrin Kogel, Theodoros Ladopoulos, Nadine Siems, Britta Krieger, Barbara Bellenberg, Ralf Gold, Ilya Ayzenberg, Carsten Lukas

Abstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruth SchneiderDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.ORCID 0000-0002-0997-2725
Ann-Kathrin KogelDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Theodoros LadopoulosDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Nadine SiemsDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Britta KriegerInstitute of Neuroradiology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Barbara BellenbergInstitute of Neuroradiology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Ralf GoldDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Ilya AyzenbergDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.
Carsten LukasInstitute of Neuroradiology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany.ORCID 0000-0002-8562-9697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGlobal brain volume changes in patients with myelin oligodendrocyte glycoprotein antibody-associated disease compared with healthy controls (HC) could be revealed by magnetic resonance imaging, but specific atrophy patterns of cortical structures and relation to cognitive impairment are not yet comprehensively known. Thus, we aimed to investigate cortical thickness differences in patients with myelin oligodendrocyte glycoprotein antibody-associated disease compared with HC.

methods3-Tesla brain magnetic resonance imaging was performed in 23 patients with myelin oligodendrocyte glycoprotein antibody-associated disease and 49 HC for voxel-wise group comparisons and neuropsychological testing in patients. Surface-based morphometry with region of interest-based surface analysis and region of interest-based extraction of cortical thickness was performed in patients compared with HC and in patient subgroups with and without cognitive impairment.

resultsComparing patients with myelin oligodendrocyte glycoprotein antibody-associated disease with HC, exploratory surface-based morphometry demonstrated cortical volume reduction in pericalcarine and lingual cortical regions. Region of interest-based surface analysis specified reduced cortical thickness in the adjacent pericalcarine and orbitofrontal regions in myelin oligodendrocyte glycoprotein antibody-associated disease, as well as reduced temporal cortical thickness in patients with cognitive impairment (n = 10). Patients without cognitive impairment (n = 13) showed only circumscribed cortical brain volume loss compared with HC in the pericalcarine region.

interpretationIn conclusion, cortical atrophy in myelin oligodendrocyte glycoprotein antibody-associated disease was characterized by cortical thickness reduction in the adjacent pericalcarine and orbitofrontal regions, with a tendency of temporal thickness reduction in cognitively impaired patients.

Indexed as

AtrophyCerebral CortexMagnetic Resonance ImagingMyelin-Oligodendrocyte GlycoproteinAdultAgedAutoantibodiesCognitive DysfunctionFemaleHumansMaleMiddle AgedAutoantibodiesMOG protein, humanMyelin-Oligodendrocyte Glycoprotein

Identifiers

PMID39054631
PMCPMC11330211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.